
Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Thoracic Oncology
- Immunotherapy
- Gastrointestinal Cancer
- Radiation Therapy
- Blood Cancer
- Central Nervous System Tumors
- Chemotherapy and Radiotherapy
- Immunology
Abstract
Citation: Clin Oncol. 2022;7(1):1928.DOI: 10.25107/2474-1663.1928
Q-Box Region Deletion of the ATRX Gene is Linked to Acquired α-Thalassemia Myelodysplastic Syndrome (ATMDS)
Chea M, Badens C, Brun S, Gris JC and Jourdan E
Department of Hematology, Nîmes University Hospital, University of Montpellier, France
Medical School, UMR_S910, Aix-Marseille University, Medical Genetics, Biological Resource Center – Tissue, DNA, Cells, La Timone Children's Hospital, Marseille, Francev
Department of Clinical Hematology, CHU Nîmes, France
*Correspondance to: Mathias Chea
PDF Full Text Case Report | Open Access
Abstract:
Acquired a-Thalassemia Myelodysplastic Syndrome (ATMDS) is a very rare form of acquired thalassemia defined by a down-regulation of α globin synthesis in a myelodysplastic context. Herein we present the case of an 87-year-old man with myelodysplastic syndrome and a progressive microcytic anemia highlighted during his biological check-ups carried out over the years. Eventually, a rare ATRX gene mutation on exon 35 leading to a premature stop codon (p.R2407*) is found confirming that carboxyl domain deletion is tightly linked to ATMDS phenotype. Moreover, this case provides further support that EPO long term treatment seems to work well with MDS presenting ATRX mutation, but larger studies need to be conducted on MDS patient cohort to evaluate the impact of these mutations on disease evolution and prognosis.
Keywords:
ATMDS; ATRX; Microcytosis
Cite the Article:
Chea M, Badens C, Brun S, Gris JC, Jourdan E. Q-Box Region Deletion of the ATRX Gene is Linked to Acquired α-Thalassemia Myelodysplastic Syndrome (ATMDS). Clin Oncol. 2022;7:1928..